冠脉通痹汤结合常规疗法治疗急性冠脉综合征临床观察  

Clinical observation of “Guanmai Tongbi Decoction”and routine therapy for the treatment of acute coronary syndrome

作　　者：王春生[1] 

机构地区：[1]北京市昌平区中西医结合医院中西结合内科,北京102208

出　　处：《上海中医药杂志》2014年第12期37-38,共2页Shanghai Journal of Traditional Chinese Medicine

摘　　要：目的观察冠脉通痹汤治疗急性冠脉综合征的临床疗效。方法将96例急性冠脉综合征患者随机分为两组,每组48例;两组均给予常规治疗,治疗组另服用冠脉通痹汤,疗程14天。结果治疗组总有效率为87.5%,对照组为75.0%;两组临床疗效有显著性差异(P<0.05);治疗后两组中医证候积分和hs-CRP含量均有明显降低(P<0.05,P<0.01),且治疗组低于对照组(P<0.05)。结论冠脉通痹汤可提高急性冠脉综合征的临床疗效,其机制与降低hs-CRP含量有关。Objective This research is to observe the clinical efficacy of treating acute coronary syndrome with＂Guanmai Tongbi Decoction＂Methods Ninety-six patients with acute coronary syndrome were randomly divided into two groups,with 48 cases in each group; both groups were given routine treatment and the treatment group was added with＂Guanmai Tongbi Decoction＂,with the course of 14 days. Results The total effective rate was 87. 5% while the control group was 75. 0%,with a significant difference between the two groups（ P〈0. 05） in clinical efficacy; After treatment,the TCM symptom score and hs-CRP content significantly decreased（ P〈0. 05,P〈0. 01）,and the treatment group was lower than the control group（ P〈0. 05）. Conclusion ＂Coronary Tongbi Decoction＂can improve the clinical efficacy of treating acute coronary syndrome and its mechanism is associated with reducing hs-CRP content.

关 键 词：急性冠脉综合征 冠脉通痹汤 超敏C反应蛋白 

分 类 号：R541.4[医药卫生—心血管疾病]